Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Galapagos ADR Representing Ord Shs GLPG

Healthcare Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GLPG)

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Newsfile May 30, 2024

Galapagos announces departure of CSO Piet Wigerinck later this year

GlobeNewswire June 22, 2021

Galapagos increases share capital through subscription right exercises

GlobeNewswire June 7, 2021

SELECTION study on filgotinib in ulcerative colitis published in The Lancet

GlobeNewswire June 4, 2021

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

GlobeNewswire May 27, 2021

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

GlobeNewswire May 18, 2021

Galapagos refocuses pipeline and rightsizes operations  

GlobeNewswire May 6, 2021

Transparency notification received from The Capital Group

GlobeNewswire May 4, 2021

Galapagos creates new subscription right plans

GlobeNewswire April 30, 2021
View More News ››

Opinion & Analysis (NDAQ:GLPG)

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Streetwise Reports July 16, 2019
View More Opinion ››

Bullboard Posts (NDAQ:GLPG)

Be the first to post on this bullboard.

Ciscom Corp.

Ciscom Corp.

Ciscom Corp. is a Canada-based holding (roll-up) company. The Company is acquiring and managing companies in the information ...
View More »